The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.
 
Mrinal M. Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice; touchIME
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Ikena Oncology; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Ezra Rosen
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Checkmate Pharmaceuticals; CVS; Delcath Systems; Foundation Medicine; Guardant Health; Illumina; KAHR Medical; Pfizer; Pfizer; PMV Pharma (I); SAGA Diagnostics; Scarce; Seagen; Sirtex Medical; Taiho Oncology; Takeda; Takeda; UpToDate; Value Analytics Labs; Xilio Therapeutics
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); PMV Pharma; PureTech (Inst); Syndax
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; CADEX Genomics; Parithera; Xact Robotics
 
Anthony Paul Conley
Consulting or Advisory Role - AADi; Applied Clinical Intelligence; Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Chordoma Foundation (Inst); EpicentRx (Inst); Ignyta (Inst); InhibRx (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MedImmune (Inst); NantHealth (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Genentech
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Siddharth Sheth
Honoraria - Medscape; Naveris
Speakers' Bureau - Exelixis
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune; Inovio Pharmaceuticals (Inst); Merck (Inst)
 
Nicholas Mai
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - IntegrityCE
Travel, Accommodations, Expenses - MJH Life Sciences
 
Erica Sgroe
Employment - Memorial Sloan-Kettering Cancer Center
Travel, Accommodations, Expenses - Memorial Sloan-Kettering Cancer Center
 
Ryan Mitchell
Employment - Memorial Sloan-Kettering Cancer Center
Travel, Accommodations, Expenses - Memorial Sloan-Kettering Cancer Center
 
Roxana Picard
Employment - Erasca, Inc
Stock and Other Ownership Interests - Erasca, Inc
Research Funding - Erasca, Inc
Travel, Accommodations, Expenses - Erasca, Inc
 
Les H. Brail
Employment - Erasca, Inc
Stock and Other Ownership Interests - Erasca, Inc; Lilly
Patents, Royalties, Other Intellectual Property - Patents related ERASCA compounds
 
Gregory Michael Cote
Honoraria - BioAtla; Gilead Sciences
Consulting or Advisory Role - C4 Therapeutics; Daiichi Sankyo/UCB Japan; Ikena Oncology; Sonata
Research Funding - Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Pyxis (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)